Xavier González

2.2k total citations
79 papers, 678 citations indexed

About

Xavier González is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Xavier González has authored 79 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 40 papers in Oncology and 22 papers in Cancer Research. Recurrent topics in Xavier González's work include Advanced Breast Cancer Therapies (30 papers), HER2/EGFR in Cancer Research (23 papers) and Breast Cancer Treatment Studies (19 papers). Xavier González is often cited by papers focused on Advanced Breast Cancer Therapies (30 papers), HER2/EGFR in Cancer Research (23 papers) and Breast Cancer Treatment Studies (19 papers). Xavier González collaborates with scholars based in Spain, United States and Italy. Xavier González's co-authors include Steven C. Springmeyer, Douglas E. Wood, Robert J. Cerfolio, Harvey O. Coxson, Chris T. Bolliger, Thomas K. Waddell, Aleix Prat, Luis Seijó, Paul Jones and Mohammed Munavvar and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Xavier González

73 papers receiving 672 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xavier González Spain 14 393 277 80 79 77 79 678
Chiyuki Okuda Japan 14 350 0.9× 298 1.1× 84 1.1× 33 0.4× 107 1.4× 33 592
Yuzo Hasegawa Japan 13 464 1.2× 334 1.2× 43 0.5× 61 0.8× 69 0.9× 36 789
Elmar Heinrich Germany 15 328 0.8× 138 0.5× 46 0.6× 64 0.8× 110 1.4× 28 555
Guozi Yang China 14 306 0.8× 228 0.8× 66 0.8× 193 2.4× 141 1.8× 33 646
Barbara O’Brien United States 14 170 0.4× 180 0.6× 53 0.7× 46 0.6× 108 1.4× 56 478
Neel Patel United Kingdom 10 176 0.4× 87 0.3× 50 0.6× 83 1.1× 79 1.0× 23 461
Andrew Bang Canada 12 240 0.6× 365 1.3× 29 0.4× 71 0.9× 57 0.7× 22 602
A. Katzenwadel Germany 13 228 0.6× 122 0.4× 46 0.6× 84 1.1× 133 1.7× 23 548
John McGregor United States 11 200 0.5× 199 0.7× 19 0.2× 87 1.1× 141 1.8× 16 865
Hironori Ishida Japan 14 211 0.5× 257 0.9× 64 0.8× 71 0.9× 222 2.9× 55 716

Countries citing papers authored by Xavier González

Since Specialization
Citations

This map shows the geographic impact of Xavier González's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier González with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier González more than expected).

Fields of papers citing papers by Xavier González

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier González. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier González. The network helps show where Xavier González may publish in the future.

Co-authorship network of co-authors of Xavier González

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier González. A scholar is included among the top collaborators of Xavier González based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier González. Xavier González is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oliveira, Mafalda, Eva Ciruelos, Guillermo Villacampa, et al.. (2025). Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clinical Cancer Research. 32(3). 468–478.
2.
3.
Gión, María, Manuel Ruíz‐Borrego, Isabel Blancas, et al.. (2025). Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial. EClinicalMedicine. 85. 103309–103309. 1 indexed citations
4.
García, José Manuel Pérez, María Gión, Manuel Ruíz‐Borrego, et al.. (2024). Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 1101–1101. 11 indexed citations
5.
Ciruelos, Eva, Tomás Pascual, Guillermo Villacampa, et al.. (2024). Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1008–1008. 4 indexed citations
6.
Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.
7.
Pascual, Tomás, Blanca González‐Farré, Fara Brasó‐Maristany, et al.. (2023). 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types. Annals of Oncology. 34. S1153–S1154. 1 indexed citations
8.
Laurentiis, Michelino De, et al.. (2023). 283P Patient profiles treated with extended adjuvant neratinib in the early access registry study: NEAR study. Annals of Oncology. 34. S297–S297. 1 indexed citations
9.
Jérusalem, Guy, Yeon Hee Park, Sara A. Hurvitz, et al.. (2022). Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discovery. 12(12). 2754–2762. 60 indexed citations
10.
Cejalvo, Juan Miguel, Claudette Falato, Lorea Villanueva, et al.. (2022). Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. Cancer Treatment Reviews. 106. 102392–102392. 18 indexed citations
11.
12.
Cortadellas, Tomás, et al.. (2021). When Is Sentinel Node Biopsy Indicated in High-Risk Ductal Carcinoma in situ? Four Hundred Sixty-Eight Cases from Three Institutions. Breast Care. 16(6). 630–636. 1 indexed citations
13.
Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2020). SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology. 16(24). 1801–1813. 9 indexed citations
14.
Adamo, Bárbara, José Alejandro Pérez Fidalgo, Eva Ciruelos, et al.. (2017). VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial. Annals of Oncology. 28. v66–v66. 1 indexed citations
15.
16.
17.
Ninane, Vincent, Christian Geltner, Michela Bezzi, et al.. (2012). Multicentre European study for the treatment of advanced emphysema with bronchial valves. European Respiratory Journal. 39(6). 1319–1325. 90 indexed citations
18.
Martín, Miguel, Pedro Sánchez‐Rovira, Montserrat Muñoz-Mateu, et al.. (2011). Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study. Annals of Oncology. 22(12). 2591–2596. 26 indexed citations
19.
Springmeyer, Steven C., Chris T. Bolliger, Thomas K. Waddell, Xavier González, & Douglas E. Wood. (2009). Treatment of Heterogeneous Emphysema Using the Spiration IBV Valves. Thoracic surgery clinics/Thorac. surg. clin.. 19(2). 247–253. 46 indexed citations
20.
Mink, Steven N., Xavier González, Krika Duke, Edgar Bautista, & Lawrence Tan. (2004). Lung Volume Reduction Surgery in Canine Model of Predominantly Upper Lobe Emphysema. CHEST Journal. 125(2). 633–643. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiyuki Okuda Breakdown of academic impact, for papers by Yuzo Hasegawa Breakdown of academic impact, for papers by Elmar Heinrich Breakdown of academic impact, for papers by Guozi Yang Breakdown of academic impact, for papers by Barbara O’Brien Breakdown of academic impact, for papers by Neel Patel Breakdown of academic impact, for papers by Andrew Bang Breakdown of academic impact, for papers by A. Katzenwadel Breakdown of academic impact, for papers by John McGregor Breakdown of academic impact, for papers by Hironori Ishida
Rankless by CCL
2026